MILAN--(BUSINESS WIRE)--The Company (MIL:SRN) has announced that it has today received a letter requesting permission to conduct, on an exclusive basis, a due diligence on the Company, under appropriate confidentiality measures on behalf of a consortium composed of Ares Life Sciences AG, Essex Woodlands Health Ventures UK Ltd, Intesa SanPaolo S.p.A. and Alpha Private Equity Funds, (‘Consortium’).
